SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics (SABS) closed an underwritten public offering of…

SAB Biotherapeutics, Inc. · PRESS-RELEASE filed Mar 19, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 19, 2026 at 16:01 ET

SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 per warrant, raising approximately $85 million in gross proceeds. The company plans to use the funds to advance its lead candidate, SAB-142, through clinical trials for type 1 diabetes and for general corporate purposes. An additional 3,311,688-share over-allotment option remains open for 30 days.

  • SAB Biotherapeutics raised $85 million in gross proceeds through a public offering.
  • Offering included 19,324,677 common shares at $3.85 and pre-funded warrants for 2,753,246 shares at $3.8499.
  • Proceeds will fund clinical development of SAB-142 for type 1 diabetes, manufacturing, regulatory activities, and general corporate use.
  • Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access